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Abstract
Background: DNA methylation contributes to the regulation of gene expression during development and cellular
differentiation. The recently developed Methylated DNA ImmunoPrecipitation (MeDIP) assay allows a
comprehensive analysis of this epigenetic mark at the genomic level in normal and disease-derived cells. However,
estimating the efficiency of the MeDIP technique is difficult without previous knowledge of the methylation status
of a given cell population. Attempts to circumvent this problem have involved the use of in vitro methylated DNA
in parallel to the investigated samples. Taking advantage of this stratagem, we sought to improve the sensitivity of
the approach and to assess potential biases resulting from DNA amplification and hybridization procedures using
MeDIP samples.
Findings: We performed MeDIP assays using in vitro methylated DNA, with or without previous DNA amplification,
and hybridization to a human promoter array. We observed that CpG content at gene promoters indeed correlates
strongly with the MeDIP signal obtained using in vitro methylated DNA, even when lowering significantly the
amount of starting material. In analyzing MeDIP products that were subjected to whole genome amplification
(WGA), we also revealed a strong bias against CpG-rich promoters during this amplification procedure, which may
potentially affect the significance of the resulting data.
Conclusion: We illustrate the use of in vitro methylated DNA to assess the efficiency and accuracy of MeDIP
procedures. We report that efficient and reproducible genome-wide data can be obtained via MeDIP experiments
using relatively low amount of starting genomic DNA; and emphasize for the precaution that must be taken in
data analysis when an additional DNA amplification step is required.
Background
DNA methylation at CpG dinucleotides is a major epige-
netic modification with direct implications in many
aspects of mammalian biology, including development and
disease [1]. In normal tissues, most promoter-associated
CpGs remain unmethylated, although DNA methylation
does occur at promoters of a small set of genes where it
generally leads to transcriptional silencing. On the other
hand, cancer cells undergo dramatic changes in the level
and distribution of DNA methylation [2]. Indeed, the
DNA methylation-dependent silencing of many tumor
suppressor genes is now recognized as a major mechanism
of gene inactivation that complements genetic lesions.
Recent technological advances have allowed the compre-
hensive analysis of DNA methylation profiles in normal
and disease-associated cells [3-6]. In particular, the Methy-
lated DNA ImmunoPrecipitation (MeDIP) assay appears
to be an efficient, reproducible and cost-effective approach
to characterize the methylome of large collections of DNA
samples [7-10]. The overall experimental strategy is based
on immunoprecipitation of methylated CpGs using a
specific anti-5-methylcytidine antibody (MeDIP), as a rule
followed by DNA amplification and hybridization to, typi-
cally, either CpG islands or promoter arrays. However,
because the efficiency of the MeDIP assay relates to the
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methylated (m)CpG content and distribution within each
particular genomic region [8], the quantification of DNA
methylation remains approximate [11,12]. To accurately
quantify CpG methylation levels, others have used in vitro
methylated DNA in parallel to the investigated, untreated
samples [e.g., [12,13]]. Here, we took advantage of this
stratagem to further evaluate potential bias resulting from
using MeDIP samples for DNA amplification, labeling and
hybridization procedures; and also to better access the
sensitivity of the overall approach.
Results and Discussion
Initially, we performed MeDIP experiments using 2 μg
of either untreated or M.SsssI methyltransferase-treated
(i.e., in vitro methylated) DNA obtained from the
SiLALL cancer cell line [14]. To validate the MeDIP
resulting samples in terms of CpG methylation yield, we
analyzed by real-time PCR the enrichment levels for sev-
eral CpG-rich promoters associated with either
expressed (ACTB; GAPDH) or silent (PCDHGA12;
RPIB9) genes in SiLALL cells (Figure 1). As expected,
these promoter regions were similarly enriched in
MeDIP signals from in vitro methylated samples, inde-
pendently of the methylation status in vivo, implying
that in vitro methylation has been efficiently achieved.
Next, we went on to test whether MeDIP signals accu-
rately reflect methylation levels genome-wide. As M.SsssI
treatment is expected to methylate every CpG in the start-
ing DNA material, MeDIP enrichment is predicted in this
context to directly reflect the density of CpG dinucleotides
throughout the genome. The standard labeling protocol
for microarray hybridization typically requires 2 μg of
immunoprecipitated DNA (a yield that implies to start
with large amounts, ~20 μg, of bulk genomic DNA).
Therefore, we first pooled DNA samples that were
obtained from 10 separate MeDIP experiments using
in vitro methylated DNA (hereafter metMeDIP), and
hybridized this pool to a custom-designed human promo-
ter array (see Additional file 1 for the validation of a con-
trol set of gene promoters). For each probe, we compared
the local CpG density (which integrates the contribution
of CpGs surrounding each probe; see “Methods” section)
to the resulting metMeDIP signal. In these conditions, we
observed a marked correlation between the MeDIP signal
and CpG density (Figure 2A; square Pearson correlation
(R2) = 0,604), implying that the MeDIP assay accurately
reflected the CpG density within each particular region.
This further implied that the in vitro methylated DNA can
be used to assess the efficiency of MeDIP assays also at
the genome-wide scale, thus extending the observations
from previous studies using arrays covering either a lim-
ited set of gene promoters [13] or a single chromosome
[12]. In order to test whether the same results could be
obtained using lower amounts of starting DNA, we ampli-
fied the DNA obtained from a single metMeDIP experi-
ment using whole genome amplification or WGA
(hereafter metMeDIPWGA), a procedure that has pre-
viously been used for the processing of MeDIP samples
[15,16]. Surprisingly however, enrichment signals obtained
from this metMeDIPWGA experiment displayed lower cor-
relation with the CpG density (Figure 2B; R2 = 0,084).
Notably, we observed a loss of correlation between met-
MeDIPWGA signal and CpG content for regions sequences
with relative CpG density higher than 0.04 (Figure 2B),
indicating a strong amplification-induced bias for regions
with high CpG content.
The above results suggested an effect of WGA amplifica-
tion on the signals observed at promoter regions that
harbored high CpG content. To accurately assess the bias
introduced by DNA amplification using WGA, we first
classified the complete set of promoters covered by the
microarray into six groups, based on their CpG contents
[17] (Figure 3A). Next, we quantified the relative MeDIP
signal per promoter by calculating the average enrich-
ment signals for the probes covering each promoter
region and compared the range of methylation signals for
promoters exhibiting varying degrees of CpG content. As
shown in figure 3B, the median methylation signals in
metMeDIP assays increased proportionally with the fre-
quency of CpGs. We observed a similar correlation with
metMeDIPWGA for the CpG-low and -intermediate pro-
moters (CpG ratios between 0 and 0.6), though not for
the CpG-high promoters (Figure 3C). Indeed, both CpG-
low and CpG-intermediate promoters displayed similar
methylation profiles in metMeDIP and metMeDIPWGA
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Figure 1 Validation of MeDIP assay using in vitro methylated
DNA. DNA samples from the human cell line SilALL were
methylated in vitro (+ M.SssI) or not, and subjected to MeDIP assay.
Relative enrichment at normally methylated (PCDHGA12 and RPIB9)
or unmethylated (ACTB and GAPDH) gene promoters was analyzed
by real-time quantitative PCR. Both the PCDHGA12 and RPIB9 gene
promoters were previously found to be commonly methylated in T-
ALLs and derived cell lines [27]. Results shown represent the mean
values of triplicate PCRs; and are representative of three
independent experiments.
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Figure 2 Assessment of MeDIP efficiency using in vitro methylated DNA. (A-B) Scatter plots of the metMeDIP (A) and metMeDIPWGA (B)
assays showing the enrichment levels (MeDIP signals) for all probes in the microarray relative to the CpG density in each individual probe
surrounding region. R2 = square Pearson correlation.
B C
1 2 3 4 5 6
CpG ratio (obs/exp)
0 0.2 0.4 0.6 0.8 1.0 1.2
1000
800
600
400
200
0
N
u
m
b
er
 o
f 
p
ro
m
o
te
rs
A
D
metMeDIP
M
eD
IP
 s
ig
n
al
 (
lo
g
2)
1 2 3 4 5 6
4
2
0
-2
metMeDIPWGA
M
eD
IP
 s
ig
n
al
 (
lo
g
2)
4
2
0
-2
-4
1 2 3 4 5 6
Ex. 1:  Low CpG content
Chr1:245,080,000-245,088,000
Ex. 2:  Intermediate  CpG content  
(No CpG Island)
Chr1:43,416,000-43,424,000
Ex. 3:  High CpG content 
(CpG Island)
Chr9:14,300,000-14,308,000
CpG  island
MeDIPNoWGA
MeDIPWGA
Figure 3 WGA shows a bias against CpG-rich promoters. (A) The histogram represents the distribution of observed versus expected CpG
frequencies for all gene promoters analyzed. Six promoter populations were defined based on their CpG contents (vertical lines). (B-C) Box plots
showing the MeDIP signals per promoter from metMeDIP (B) or metMeDIPWGA (C) assays according to the promoter populations defined in (A).
(D) Examples of methylation profiles for promoters with low, intermediate and high CpG contents. The presence of a CpG island in the gene
promoter shown in example #3 is indicated.
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experiments (Figure 3D, examples 1 and 2), whereas
CpG-high promoters displayed high methylation signals
in the metMeDIP experiment only (Figure 3D, example
#3 of a CpG island containing promoter). Overall, these
data demonstrated that MeDIP signals obtained from
in vitro methylated DNA accurately correlate with the
CpG content of gene promoters, highlighting its adequate
use to quantify methylation levels. They also reveal a
strong bias against CpG-rich promoters when treated by
WGA, most probably due to the poor amplification of
CG-rich sequences during the PCR step.
Finally, we asked whether we could improve the sensi-
tivity of MeDIP assay in order to use reduced amount
of starting DNA, while keeping with unbiased results.
Initially, we repeated the assays using either different
concentrations of the precipitating antibody or
decreased numbers of WGA cycles, but did not observe
significant improvement then (data not shown). Subse-
quently, by modifying the labeling conditions (for
details, see “Methods” section and Additional file 2), we
reproducibly obtained enough labeled material for array
hybridization, even when starting from a single metMe-
DIP experiment. Strikingly, these “single metMeDIP”-
based experiments yielded as good correlations between
MeDIP signals and CpG contents at gene promoters as
those observed previously when starting from metMe-
DIP DNA pools (see Figure 4A-C; R2 = 0,9163). To
demonstrate that this was also the case when using sam-
ples from M.SsssI untreated SIALL genomic DNA, we
further labeled and hybridized the DNAs that were
immunoprecipitated from either one or ten pooled
MeDIP experiments. As shown in figure 4D-F, both
types of starting MeDIP experiments yielded consistent
and highly correlated results (R2 = 0.9009), thus demon-
strating that hybridization of MeDIP materials obtained
from only 2 μg of starting genomic DNA does not in
fact require prior amplification.
Conclusion
We have used in vitro methylated DNA samples in an
unbiased approach to assess the efficiency of the MeDIP
procedure. Verifying genome-wide correlations between
MeDIP signals from in vitro methylated DNA samples
and actual CpG contents at gene promoters was impor-
tant since in vitro methylated DNA was proposed to be
used routinely to assess absolute methylation levels in
MeDIP assays [e.g. [12,13]]. In this regard, a recently
developed algorithm aimed at the estimation of methyla-
tion levels at individual promoters, has been implemen-
ted to also take into account the signals from in vitro
methylated DNA samples [12]. Recent works using sin-
gle-base resolution maps of methylated cytosines in
human embryonic stem cells have identified cytosine
methylation in a non-CpG context [6,18]. Because
MeDIP apparently enables the capture of non-CpG
methylation [19], experimental and in silico attempts to
quantify absolute levels of DNA methylation should also
take this particular feature into account. While our
results reveal the loss of signal for CpG-rich regions fol-
lowing WGA, quantitative information can still be
retrieved for low and intermediate CpG promoters
(Figure 3). The latter observation is particularly relevant
as it is currently thought that these regions precisely
undergo de novo methylation in transformed cells [e.g.,
[20]]. These points need to be considered when only a
limited amount of DNA is available (e.g., in analysis of
tumor tissues or rare cell subpopulations) and amplifica-
tion-based methods such as WGA are unavoidable.
Notice that the bias observed after WGA amplification
in this study of DNA methylation may be of a broader
interest, as this amplification procedure is commonly
used in several other types of quantitative assays, includ-
ing ChIP-on-chip, comparative genomic hybridization
(CGH) and single nucleotide polymorphism (SNP)
[21-24]. Finally, we also demonstrate here that consis-
tent and accurate genome-wide methylation data can be
reproducibly attained in array hybridization using
MeDIP materials obtained from as little as 2 μg of start-
ing genomic DNA (an amount that is regularly available
from cancer tissue biopsies), without the need for addi-
tional amplification steps.
Methods
DNA preparation and in vitro methylation
Genomic DNA from the human T-acute lymphoblastic
leukemia cell line SilALL [14] was sonicated to a range of
300-500 bp, using a Bioruptor (Diagenode, Liège,
Belgium). In vitro methylation was achieved by incubating
the sonicated DNA with 20 units of the CpG-methyltrans-
ferase M.SssI (New England Biolabs, Frankfurt, Germany)
for 4 h at 37°C [25], followed by DNA purification with
the Qiaquick PCR kit (Qiagen, Hilden, Germany).
Methylated DNA Immunoprecipitation (MeDIP) assays
Methylated DNA was immunoprecipitated as described
previously [8] with a few modifications. Briefly, 2 μg of
denatured DNA was incubated with 2 μg of anti-5-methyl-
cytidine antibody (Eurogentec, Seraing, Belgium) in IP buf-
fer (10 mM Na-Phosphate pH 7.0, 0.14 M NaCl, 0.05%
Triton X-100) for 2 h at 4°C. Antibody-bound DNA was
collected with 40 μl of Dynabeads M-280 sheep anti-
mouse IgG (Invitrogen Dynal, Oslo, Norway) for 1 h at 4°C
on a rotating wheel and successively washed with buffer I
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl pH 8.1, 150 mM NaCl), buffer I complemented with
500 mM NaCl, LiCl buffer (250 mM LiCl, 1% IGEPAL-
CA630, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris-
HCl pH 8.1) and twice with TE (10 mM Tris·Cl, 1 mM
Jia et al. BMC Research Notes 2010, 3:240
http://www.biomedcentral.com/1756-0500/3/240
Page 4 of 6
EDTA pH 8.0). The beads were resuspended in 125 μl PK
buffer (50 mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS, 35
μg proteinase K) and incubated for 3 h at 50°C. DNA was
extracted by standard phenol/chloroform procedure and
purified as above. The DNA from one MeDIP experiment
was subjected to amplification using the WGA-2 kit
(Sigma-Aldrich, Taufkirchen, Germany). Subsequently, 2
μg of DNA from either 10 pooled samples or a WGA
amplified sample (MeDIPWGA), along with their corre-
sponding whole genomic DNA (input), were labeled using
the BioPrime Array CGH Genomic Labeling System (Invi-
trogen) and hybridized to a custom human promoter array
(Agilent, Santa Clara, USA) containing 236,992 probes, fol-
lowing the microarray manufacturer’s instructions. In
experiments shown in Figure 3, the DNA obtained from a
single MeDIP experiment (usually ~250 ng) was labeled
using a modified protocol in which Cy3-dUTP and Cy5-
dUTP were replaced by Cy3-dCTP and Cy5-dCTP during
the labeling procedure. In these conditions, we generally
obtained more than 4 μg of efficiently labeled DNA (Note
that, when using the classical labeling conditions and 2 μg
of starting DNA material, we did not obtain labeled sam-
ples of high-enough quality to be hybridized onto Agilent
arrays; Additional file 2). Finally, median-normalized log2
enrichment ratios (Medip/Input) were calculated using
CoCAS software [26]. Experiments were performed in
duplicate and showed very high correlation in all cases
(R2 > 0.93).
CpG density
To integrate the contributions of CpG dinucleotides
around each probe to the MeDIP signal, we calculated a
local CpG density. To compute CpG densities, we
weighted the CpGs found in the 800 bp genomic region
surrounding each probe by their distance to the probe
using a Gaussian distribution.
Additional material
Additional file 1: Confirmation of methylation results obtained by
qPCR. Methylation profiles obtained in pooled metMeDIP or MeDIP
hybridization experiments for gene promoters tested by qPCR in Figure 1
are shown.
Additional file 2: Assessment of the efficiency of the labeling
procedure. Control DNA and MeDIP samples were labeled with either
Cy5-dUTP or Cy5-dCTP and the labeling efficiency was compared.
List of abbreviations used
MeDIP: Methylated DNA Immunoprecipitation; WGA: Whole Genome
Amplification; CGH: comparative genomic hybridization; SNP: single-
nucleotide polymorphism.
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Figure 4 Similar results are obtained from pooled or single MeDIP assays. The average MeDIP signal per promoter obtained from pooled
(A) or single (B) metMeDIP and pooled (D) or single (E) MeDIP assays were plotted against the CpG content of each promoter region. (C, F)
Correlation between pooled and single metMeDIP (C) or MeDIP (F) experiments (R2 = square Pearson correlation).
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